RA-9 NEW
| Price | $45 | $68 | $113 |
| Package | 25mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-22 |
Product Details
| Product Name: RA-9 | CAS No.: 919091-63-7 |
| Purity: 99.31% | Supply Ability: 10g |
| Release date: 2026/04/22 |
Product Introduction
Bioactivity
| Name | RA-9 |
| Description | RA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs) with a favorable toxicity profile and anticancer activity, particularly effective in inducing apoptosis in ovarian cancer cell lines. |
| Animal Research | Mice were inoculated i.p. with 100,000 ES-2 cells (in 100 μl DMEM) stably expressing GFP.?When tumor was detectable (approx.?6 days post inoculation), mice were randomly assigned into two groups receiving RA-9 or 0.9% saline.?Treatment with RA-9 was given i.p. on a one-day on, two-days off schedule.?The control group received the vehicle alone at the same schedule.?Working concentrations of RA-9 (10 mg/ml) were reached by dissolution in Cremophor EL and polyethylene glycol 400 (Sigma).?Prior to each injection RA-9 was further diluted in 0.9% saline (working concentration 1mg/ml).?To monitor for tumor growth, RA-9 treated and control mice were imaged with an IVIS SpectrumCT Pre-clinical in vivo imaging system (PerkinElmer) every other day.?Animals were sacrificed when abdomens became distended to twice normal size. |
| In vitro | The characterization of RA-9 as a small-molecule inhibitor of proteasome-associated DUBs.?Treatment with RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors.?Loss of cell viability following RA-9 exposure is associated with an unfolded protein response as mechanism to compensate for unsustainable levels of proteotoxic stress. |
| In vivo | In vivo treatment with RA-9 retards tumor growth, increases overall survival, and was well tolerated by the host. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4 mg/mL (10.95 mM), Sonication and heating to 80℃ are recommended. |
| Keywords | Unfolded | survival | Response | RA-9 | RA9 | RA 9 | Protein | ovarian | Inhibitor | inhibit | DUBs | deubiquitinating enzymes (DUBs) | Deubiquitinase | cells | cancer | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Highly Selective Inhibitor Library | DNA Damage & Repair Compound Library | Bioactive Compound Library | Endoplasmic Reticulum Stress Compound Library | Ubiquitination Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Covalent Inhibitor Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
![CCR2-RA-[R]](https://img.chemicalbook.com/ProductImageEN2/2025-11/Large/e280734e-40ce-47cc-bae7-5badc1d78e18.png)
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
| $39.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
VIP2Y
|
Shenzhen Nexcon Pharmatechs Ltd.
|
2026-07-01 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY